Recently
We published another article on stroke. When a stroke occurs, dropping brain pH triggers a hidden crisis. In our new paper we reveal how acidosis may alter Junctional Adhesion Molecules.
Progress:
step 3/6
1 / Project Design
Great companies begin with a clear hypothesis. In this initial phase, we focus on identifying market inefficiencies and testing core assumptions. By prioritizing rapid prototyping and technical feasibility, we ensure the foundational concept is sound before significant resources are deployed.
2 / Initial Publications
Before scaling, we must prove demand. We transition the project from stealth to public visibility through strategic waitlists, open-source repositories, or preliminary beta launches. This captures early-adopter interest and validates our core hypothesis using real-world user data.
3 / Business Model Development
This is where a project becomes a viable business. We convert validated market demand into a sustainable commercial framework. This step defines the Ideal Customer Profile (ICP), maps the competitive landscape, and establishes a scalable monetization and pricing strategy.
4 / Corporate Formation
To prepare for institutional investment, the venture must be properly structured. We formalize the enterprise, while securing intellectual property assignments, structuring founder vesting schedules, and architecting a clean, investor-ready capitalization table.
5 / Minimum Viable Product
With the corporate structure in place, focus shifts to executing the Minimum Viable Product (MVP). During this phase, founders typically secure Pre-Seed capital from angel investors or micro-VCs to fund core operations, onboard the first cohort of paying customers, and rapidly iterate based on usage analytics.
6 / Seed Funding & Growth
Traction unlocks scale. Having achieved early Product-Market Fit, the venture is now positioned to raise institutional Seed capital (typically $1M–$4M). This injection of capital is deployed to recruit elite engineering and go-to-market teams, transitioning the company from building a product to scaling a business.
Our
Story
smart protein drugs that listen to the body
Our Mission
To fundamentally redefine targeted therapy by engineering smart, pH-sensitive biologics that dynamically adapt to the disease microenvironment, delivering unprecedented precision and safety to patients.
Our Vision
To lead the global transition toward fully programmable therapeutics, eradicating off-target drug toxicity and unlocking new frontiers in the treatment of complex inflammatory and ischemic conditions.
Get to Know Us
At Ophyra Biotechnology, we are pioneering the next generation of precision medicine through the development of programmable, environment-specific therapeutics. Traditional biologic treatments often face a critical bottleneck: systemic, off-target effects that limit their safety and clinical potential. We are overcoming this barrier by engineering advanced "bio-betters"—smart peptide and protein drugs that remain inactive until they reach the exact site of disease. By leveraging cutting-edge computational protein engineering, our therapeutics are designed to respond dynamically to localized biochemical cues, specifically the distinct pH shifts characteristic of ischemic and inflammatory tissues. This targeted activation ensures maximum efficacy precisely where it is needed, safeguarding healthy tissue and transforming the therapeutic landscape.